Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
University of Missouri
mi
from
Columbia, MO
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
University of Missouri
mi
from
Columbia, MO
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Deaconess Billings Clinic
mi
from
Billings, MT
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Deaconess Billings Clinic
mi
from
Billings, MT
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
New York Oncology
mi
from
Albany, NY
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
New York Oncology
mi
from
Albany, NY
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Univ of North Carolina
mi
from
Chapel Hill, NC
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Presbyterian Hospital Cancer Center
mi
from
Charlotte, NC
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Presbyterian Hospital Cancer Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Dayton Oncology And Hematology
mi
from
Kettering, OH
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Dayton Oncology And Hematology
mi
from
Kettering, OH
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Providence Portland Medical Center
mi
from
Portland, OR
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Hematology and Oncology Associates of NEPA
mi
from
Dunmore, PA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Hematology and Oncology Associates of NEPA
mi
from
Dunmore, PA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Mary Crowley Research Center
mi
from
Dallas, TX
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Mary Crowley Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Tyler Cancer Center
mi
from
Tyler, TX
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Tyler Cancer Center
mi
from
Tyler, TX
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Rainer Oncology Professional Services
mi
from
Puyallup, WA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Rainer Oncology Professional Services
mi
from
Puyallup, WA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
Cancer Care Northwest
mi
from
Spokane, WA
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
University of Wisconsin
mi
from
Madison, WI
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated:  4/5/2018
mi
from
Linz,
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Status: Enrolling
Updated: 4/5/2018
mi
from
Linz,
Click here to add this to my saved trials
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/6/2018
START Midwest
mi
from
Grand Rapids, MI
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/6/2018
START Midwest
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/6/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/6/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/6/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/6/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/6/2018
Massachusetts General Hospital
mi
from
Boston, MA
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/6/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  4/6/2018
Moffitt Cancer Center
mi
from
Tampa, FL
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 4/6/2018
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/6/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/6/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/6/2018
Midwestern Regional Medical Center
mi
from
Zion, IL
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/6/2018
Midwestern Regional Medical Center
mi
from
Zion, IL
Click here to add this to my saved trials
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/6/2018
Massachusetts General Hospital, Yawkey Center for Outpatient Care
mi
from
Boston, MA
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/6/2018
Massachusetts General Hospital, Yawkey Center for Outpatient Care
mi
from
Boston, MA
Click here to add this to my saved trials
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/6/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/6/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/6/2018
Memorial Sloan-Kettering
mi
from
New York, NY
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/6/2018
Memorial Sloan-Kettering
mi
from
New York, NY
Click here to add this to my saved trials
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/6/2018
Carolinas Hematology-Oncology Associates
mi
from
Charlotte, NC
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/6/2018
Carolinas Hematology-Oncology Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/6/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/6/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/6/2018
Cleveland Clinic
mi
from
Cleveland, OH
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/6/2018
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/6/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/6/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/6/2018
Swedish Cancer Institute
mi
from
Seattle, WA
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/6/2018
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/6/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/6/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/6/2018
Institut Gustave Roussy ( Site 0049)
mi
from
Villejuif,
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of HKI-272 In Subjects With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/6/2018
Institut Gustave Roussy ( Site 0049)
mi
from
Villejuif,
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
University of Colorado Cancer Center
mi
from
Aurora, CO
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
Mid Florida Hematology and Oncology Centers
mi
from
Orange City, FL
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
Mid Florida Hematology and Oncology Centers
mi
from
Orange City, FL
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
Edward M Kaplan, MD & Associates
mi
from
Skokie, IL
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
Edward M Kaplan, MD & Associates
mi
from
Skokie, IL
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
Berkshire Hematology Oncology Services
mi
from
Pittsfield, MA
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
Berkshire Hematology Oncology Services
mi
from
Pittsfield, MA
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
Jackson Oncology Associates
mi
from
Jackson, MS
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
Jackson Oncology Associates
mi
from
Jackson, MS
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
Northshore Hematology Oncology
mi
from
East Setauket, NY
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
Northshore Hematology Oncology
mi
from
East Setauket, NY
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
Trinity Cancer Center
mi
from
Minot, ND
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
Trinity Cancer Center
mi
from
Minot, ND
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
Gettysburg Cancer Center
mi
from
Gettysburg, PA
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
Gettysburg Cancer Center
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
Carolina Blood and Cancer Care
mi
from
Rock Hill, SC
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
Carolina Blood and Cancer Care
mi
from
Rock Hill, SC
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
West Clinic
mi
from
Germantown, TN
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
West Clinic
mi
from
Germantown, TN
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
Tennessee Cancer Specialists
mi
from
Knoxville, TN
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
Tennessee Cancer Specialists
mi
from
Knoxville, TN
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
Thomas Spann Clinic Oncology
mi
from
Corpus Christi, TX
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
Thomas Spann Clinic Oncology
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated:  4/9/2018
Providence Regional Medical Center
mi
from
Everett, WA
Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing
Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.
Status: Enrolling
Updated: 4/9/2018
Providence Regional Medical Center
mi
from
Everett, WA
Click here to add this to my saved trials